Targeting nerve growth factor: an Achilles' heel for tumors?

Elizabeth Repasky1, Hemn Mohammadpour2

  • 1Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA elizabeth.repasky@RoswellPark.org Hemn.Mohammadpour@RoswellPark.org.

Insights

Researchers explored targeting nerve growth factor (NGF) with chimeric antigen receptor (CAR) T cells. Neutralizing NGF with CAR T cells may enhance anti-tumor immunity and remodel the tumor microenvironment.

Area of Science:

  • Oncology
  • Immunology
  • Neuroscience

Background:

  • Tumor innervation, driven by the sympathetic nervous system, promotes tumor progression and immune evasion.
  • Catecholamines from nerves activate tumor cell receptors, boosting growth and therapy resistance.
  • Nerve growth factor (NGF) produced by tumors is crucial for innervation and a potential therapeutic target.

Purpose of the Study:

  • To examine the efficacy of NGF-targeting chimeric antigen receptor (CAR) T cells.
  • To investigate the impact of NGF neutralization on CAR T-cell function.
  • To assess the remodeling of the tumor microenvironment by NGF-neutralizing CAR T cells.

Main Methods:

  • Utilized NGF single-chain variable fragment (scFv)-secreting CAR T cells.
  • Analyzed CAR T-cell function following NGF neutralization.
  • Evaluated changes in the tumor microenvironment.

Main Results:

  • NGF neutralization by CAR T cells impacts CAR T-cell function.
  • CAR T-cell-mediated NGF neutralization can remodel the tumor microenvironment.
  • Exploiting tumor-derived NGF may enhance anti-tumor immune activity.

Conclusions:

  • NGF is a critical factor in tumor progression and immune escape.
  • NGF-targeting CAR T cells represent a novel therapeutic strategy.
  • Targeting tumor-derived survival factors can be leveraged to enhance anti-tumor immunity.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
75.9K